Mainz BioMed

Name: Mainz BioMed
Address: Mainz Biomed N. V. Sirius Gutenberg Park, Robert-Koch-Straße 50, Mainz, 55129, DE
Telephone: +496131265140
Price range: Not Applicable

Startseite
Deutschland
Mainz
Mainz BioMed

Mainz BioMed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. https://mainzbiomed.com/

17/02/2026

Mainz Biomed N.V. (NASDAQ: MYNZ) announced that on February 13, 2026, it entered into a securities purchase agreement for a USD 6.0 million private placement with David Lazar. The financing will be completed in two tranches of USD 3.0 million through the issuance of Convertible Non-Redeemable Preferred Stock.

In connection with the transaction, David Lazar was appointed Chairman of the Board of Directors. As Chair, he emphasized the Company’s focus on advancing its pancreatic cancer screening program in the U.S. while pursuing strategic opportunities to create long-term value for stockholders.

As part of this strategic shift, Mainz Biomed will streamline operations, reduce costs, and extend its runway by evaluating the sale of its colorectal cancer screening assets and winding down its German subsidiary.

Link to the full press release: https://mainzbiomed.com/mainz-biomed-announces-6-0-usd-million-private-placement-and-strategic-update/

$MYNZ

27/01/2026

Colorectal cancer is preventable, but almost 50% of Europeans aged 50–74 aren’t getting screened on time.

Far too many individuals postpone screening not out of neglect, but because the process can feel invasive, time-consuming, or intimidating. By shifting from hospital-based procedures to at-home, non-invasive solutions, we remove the friction that often keeps people from acting.

The result:
✔️ Higher engagement
✔️ Earlier detection
✔️ Greater health equity
✔️ More lives saved

20/01/2026

What You Eat Shapes Your Colorectal Health

Research continues to show a strong connection between diet and colorectal cancer risk.

✔️ More fiber (fruits, vegetables, legumes, whole grains)
✔️ More calcium (dairy, tofu, leafy greens)
❌ Less processed meats and ultra-processed foods

Small daily choices can support a healthier microbiome and reduce long-term risk.

At Mainz Biomed, we believe prevention begins with awareness, healthy habits, and accessible early detection tools that empower people to protect their health.

16/01/2026

Imagine a Europe where colorectal cancer is routinely prevented instead of discovered late.
That’s the opportunity accessible screening creates.

💡 If you are aged 50–74 — or know someone who is — ask about screening options like ColoAlert.

💡 If you work in healthcare, policy, HR, or wellbeing, help raise awareness. Early detection saves lives.

Mainz Biomed is helping bring that future closer, transforming colorectal cancer detection into true prevention.

In Europe, ColoAlert is already available, making early detection more accessible and helping reduce colorectal cancer rates. Our goal: empower people to take part in proactive awareness and solutions.

05/01/2026

From Mainz Biomed, we want to wish you all a great 2026!

As we begin the year, we’d like to thank our team, partners, and supporters who made 2025 such an impactful year.

Together, we advanced our mission to make early cancer detection accessible, accurate, and routine:

Launched eAArly DETECT 2 clinical study in the U.S. to evaluate our next-generation Test on Advanced Adenomas in ~2,000 average-risk patients
Expanded ColoAlert® across the UK, Switzerland, and South America through key partnerships.

Advanced pancreatic cancer research with Liquid Biosciences, achieving 100% sensitivity and 95% specificity in a non-invasive blood-based feasibility study.

In 2026, our focus is clear: completing eAArly DETECT 2, advancing ReconAAsense toward FDA approval, and continuing progress in pancreatic cancer screening.

Here’s to a year of innovation, collaboration, and life-saving impact.

$MYNZ

30/12/2025

More and more, it’s becoming clear that what we eat shapes our long-term health – especially our colorectal health.

Consuming higher levels of ultra-processed foods had a greater risk of developing precancerous colorectal polyps, early growths that can become cancer if unnoticed.

We’re talking about foods many of us rely on:
✔ quick meals
✔ sugary beverages
✔ packaged snacks
✔ products filled with additives

Convenient? Yes.

But in excess, these foods may alter the gut microbiome, drive inflammation, and raise risks we don’t see or feel right away.

At Mainz Biomed, this matters deeply to us, because colorectal cancer is among the world’s most preventable cancers when detected early. That’s why we created ColoAlert, our at-home stool DNA test. By bringing cutting-edge screening into the home, we make early detection more accessible and comfortable. Instead of waiting for symptoms, people can screen proactively, privately, and routinely.

Because prevention shouldn’t be difficult. It should fit into real life.

22/12/2025

Over the past months, Mainz Biomed has made important progress as we continue to expand our mission in early cancer detection.

Our eAArly DETECT 2 study is moving forward as a key step toward launching our upcoming ReconAAsense FDA pivotal study for colorectal cancer, planned for 2026.

These milestones bring us closer to offering accurate, non-invasive, and accessible screening solutions that can make a real difference in prevention and patient outcomes.

Early detection saves lives — and we’re committed to making it more available for everyone.

18/12/2025

As the U.S. population ages, the demand for accessible and accurate health screenings is paramount. With over 112 million Americans aged 50 and older, a figure set to soar to 157 million in the next decade, we must take action.

It is crucial to ensure that reliable testing options are universally available to facilitate early detection and enhance health outcomes.

At Mainz Biomed, we’re dedicated to pioneering innovative diagnostic solutions that make colorectal cancer screening simple, accurate, and accessible for everyone.

When testing is within reach, prevention becomes a reality.

$MYNZ

17/12/2025

At Mainz Biomed, we believe prevention isn’t passive. It’s proactive, data-driven, and transformative.

Through the eAArly DETECT 2 study, we aim to prove that advanced molecular testing can detect precancerous lesions long before disease develops.

This changes everything.
Because prevention isn’t about waiting, it’s about acting early, with precision and purpose.

Together, we can shift global perception: from detecting cancer to preventing it.

16/12/2025

The importance of working with a partner with cutting-edge technology and deep scientific expertise. This is especially true for devastating diseases such as pancreatic cancer.

That’s why we’re proud to work with Liquid Biosciences and their EMERGE AI platform, which uses advanced machine learning to uncover molecular patterns that traditional methods can’t detect.

In our latest work together, the EMERGE platform identified 18 licensed biomarkers across multiple candidate panels. The leading panel achieved 100% sensitivity and 95% specificity, successfully distinguishing pancreatic cancer patients from healthy controls in a 30-subject cohort, covering different disease stages and precursors.

If these results are replicated in future development, this technology has the potential to make our PancAlert test a reliable screening tool for pancreatic cancer. 💙

15/12/2025

Science moves us forward.
Every day, through research and dedication, we build progress in early cancer detection.

We envision a world where colorectal cancer diagnosis becomes prevention, and every test gives hope for a longer, healthier life.

Adresse

Mainz Biomed N. V. Sirius Gutenberg Park, Robert-Koch-Straße 50
Mainz
55129

Telefon

+496131265140

Webseite

https://mainzbiomed.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Mainz BioMed erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.